In a multicenter, randomized, double-blind, placebo-controlled trial, 33 cachectic COPD patients were randomly assigned PR with intravenous ghrelin (2 μg/kg) or placebo twice daily for 3 weeks in hospital. This evidence concerns the gene GHRL and chronic obstructive pulmonary disease.